Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Mycosis Fungoides 5Endometrial Neoplasms 5Breast Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Thyroid Neoplasms 3Sezary Syndrome 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Brenner Tumor 3Brain Neoplasms 3

Interventions

Cisplatin 32Radiotherapy, Intensity-Modulated 21Magnetic Resonance Spectroscopy 21Radiotherapy 16Specimen Handling 15Radiation 14Carboplatin 14pembrolizumab 13Platinum 121,2-diaminocyclohexaneplatinum II citrate 11Paclitaxel 8Chemoradiotherapy 7Biopsy 7Taxes 6Surveys and Questionnaires 6Cetuximab 6Nivolumab 5Surgical Procedures, Operative 4Observation 4Fluorodeoxyglucose F18 4Drug Therapy 4Docetaxel 4durvalumab 3(225)Ac-DOTA-c(RGDyK) 3toripalimab 2cemiplimab 2atezolizumab 2aldesleukin 2X-Rays 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × Immunoglobulin G × 1 year × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡